Patents Assigned to Laboratoire Francais du Fractionnement et des Biotechnologies
  • Method for stabilising an immunoglobulin G composition in liquid form
    Patent number: 9463241
    Abstract: This invention is related to a stabilizing formulation for immunoglobulins G compositions comprising a sugar alcohol, glycine and a non-ionic detergent, which is suitable for the stabilization of immunoglobulins G compositions in liquid form and in lyophilized form. The invention also relates to an immunoglobulins G composition in liquid form or in lyophilized form comprising said stabilizing formulation.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: October 11, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Annie Bardat, Edith Begin, Nassirah Khandoudi, Olivier Just, Sami Chtourou, Roland Schmitthaeusler
  • GLA-DOMAINLESS FACTOR X
    Publication number: 20160177286
    Abstract: The present invention relates to a protein consisting of the sequence SEQ ID No.: 11 or 25 or 26, directly bound, or bound via a linker, especially -Arg-Lys-Arg-, to the sequence SEQ ID No.: 6.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 23, 2016
    Applicants: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS, UNIVERSITE GRENOBLE I JOSEPH FOURIER
    Inventors: Aline Thomas, Marie-Claire Dagher, Raphael Marlu, Benoit Polack, Jean-Luc Plantier, Alexandre Fontayne, Toufik Abache
  • Method for purifying GLA-domain coagulation proteins
    Patent number: 9359610
    Abstract: A method for purifying GLA-domain coagulation proteins, includes the following steps: a) bringing a sample containing one or more GLA-domain coagulation proteins into contact with an affinity substrate on which nucleic aptamers which bind specifically to the GLA-domain coagulation proteins are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the GLA-domain coagulation protein(s) in a purified form.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: June 7, 2016
    Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
    Inventors: Gerald Perret, Sami Chtourou, Nicolas Bihoreau
  • TRANSGENIC FACTOR VII HAVING A SPECIFIC N-GLYCOSYLATION AND SUBSTANTIALLY HOMOGENOUS ISOELECTRIC POINT
    Publication number: 20160152965
    Abstract: The present invention relates to a factor VII composition having a substantially homogeneous isoelectric point and to a method for formulating such a composition. The present invention also relates to the therapeutic use of a factor VII composition having a substantially homogeneous isoelectric point.
    Type: Application
    Filed: June 10, 2014
    Publication date: June 2, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Guillaume Chevreux
  • Anti-FH aptamers, method for producing same, and uses thereof
    Patent number: 9347052
    Abstract: The invention relates to nucleic acid aptamers binding specifically to factor H, to a method for obtaining same, and to the uses thereof, in particular for the purposes of purifying factor H.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: May 24, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Gerald Perret, Agnes Cibiel
  • METHOD FOR PURIFYING ACTIVE GLA-DOMAIN COAGULATION PROTEINS
    Publication number: 20160138001
    Abstract: The invention relates to a method for purifying biologically active GLA-domain coagulation proteins, comprising the following steps: a) bringing a sample that contains one or more GLA-domain coagulation proteins and may contain biologically inactive molecules of GLA-domain protein(s), into contact with an affinity support on which nucleic aptamers that bind specifically to at least one biologically active GLA-domain coagulation protein are immobilized, in order to form complexes between (i) said nucleic aptamers and (ii) said GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering said biologically active GLA-domain coagulation protein(s) in a purified form.
    Type: Application
    Filed: November 10, 2015
    Publication date: May 19, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Gerard Perret, Nicolas Bihoreau, Laurent Siret
  • Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
    Patent number: 9339530
    Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilized concentrates of said proteins.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: May 17, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Michel Nogre, Pierre Porte, Michel Tellier
  • Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
    Patent number: 9320779
    Abstract: Process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilized concentrates of said proteins.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: April 26, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Michel Nogre, Pierre Porte, Michel Tellier
  • TREATMENT OF BLEEDING WITH LOW HALF-LIFE FIBRINOGEN
    Publication number: 20160106815
    Abstract: The invention provides low-half life fibrinogen as a result of recombinant expression or enzymatic and chemical removal. The low-half life fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
    Type: Application
    Filed: November 5, 2015
    Publication date: April 21, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
  • CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B LYMPHOID HEMATOPOIETIC PROLIFERATIONS
    Publication number: 20160060350
    Abstract: The present invention relates to a monoclonal antibody directed against the CD20 antigen, wherein the variable region of each of the light chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 5, the variable region of each of the heavy chains thereof is encoded by a sequence which shares at least 70% identity with murine nucleic acid sequence SEQ ID No. 7, and the constant regions of light and heavy chains thereof are constant regions from a non-murine species, as well as for activation of Fc?RIIIA receptors in immune effector cells, and for the manufacture of a drug especially for the treatment of leukaemia or lymphoma.
    Type: Application
    Filed: August 17, 2015
    Publication date: March 3, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe DE ROMEUF, Christine GAUCHER, Jean-Luc TEILLAUD, Jean-Francois PROST
  • NOVEL MEDICAMENTS COMPRISING AN ANTIBODY COMPOSITION ENRICHED WITH PREDOMINANT CHARGE ISOFORM
    Publication number: 20160046722
    Abstract: The present invention lies in the technical field of antibody therapies involving a mechanism of target-cell destruction by ADCC. It relates to purified antibody compositions, obtained by chromatographic fractionation of the various charge isoforms naturally present in an antibody composition and combining one or more chromatographic fractions corresponding to the predominant peak of the chromatogram, the resulting monoclonal antibody composition being enriched in said predominant peak, said peak representing at least 85% of the chromatogram of the composition obtained, for use as a medicament.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 18, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Guillaume Chevreux, Nicolas Bihoreau
  • METHOD FOR PREPARING A CONCENTRATE OF FACTOR XI
    Publication number: 20160024488
    Abstract: The invention concerns a concentrate of human Factor XI having high specific activity prepared using a method comprising a filtration-adsorption step and a chromatography step on cation exchange resin. The concentrate obtained is fully adapted for therapeutic use as substitution therapy in cases of Factor XI deficiency.
    Type: Application
    Filed: October 2, 2015
    Publication date: January 28, 2016
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Jean-Francois Martin
  • METHOD FOR PURIFYING OR DETECTING A TARGET PROTEIN
    Publication number: 20160009761
    Abstract: The invention relates to a method for purifying or detecting a target protein present in a solution, wherein said method comprises, before carrying out the purification or detection step itself, the step of contacting said solution with an aptamer binding specifically to said target protein, wherein said aptamer does not bind to any protein homologous to said target protein that could also be present in the solution.
    Type: Application
    Filed: September 22, 2015
    Publication date: January 14, 2016
    Applicant: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Laurent Siret, Abdessatar Chtourou, Frederic Dhainaut, Gerald Perret
  • Monoclonal antibody directed against CD20 antigen
    Patent number: 9234045
    Abstract: The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of Fc?RIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: January 12, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christophe De Romeuf, Christine Gaucher, Jean-Luc Teillaud, Jean-François Prost
  • Method for purifying active GLA-domain coagulation proteins
    Patent number: 9212365
    Abstract: A a method for purifying biologically active GLA-domain coagulation proteins, includes the following steps: a) bringing a sample that contains one or more GLA-domain coagulation proteins and may contain biologically inactive molecules of GLA-domain protein(s), into contact with an affinity substrate on which nucleic aptamers that bind specifically to at least one biologically active GLA-domain coagulation protein are immobilized, in order to form complexes between (i) the nucleic aptamers and (ii) the GLA-domain coagulation protein(s), b) releasing the GLA-domain coagulation protein(s) from the complexes formed in step a), and c) recovering the biologically active GLA-domain coagulation protein(s) in a purified form.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 15, 2015
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Gerard Perret, Nicolas Bihoreau, Laurent Siret
  • Treatment of bleeding with low half-life fibrinogen
    Patent number: 9212215
    Abstract: A fibrinogen with reduced half-life and low sialic acid content as a result of recombinant expression or enzymatic and chemical removal. The fibrinogen is useful in treating or effecting prophylaxis of bleeding particularly in situations of an acute nature in which a high initial dose and rapid decline to normal or below normal levels is desirable.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: December 15, 2015
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Frank Pieper, Anurag Relan, Erik Jordahl Forsberg
  • Concentrated human immunoglobulin composition
    Patent number: 9186401
    Abstract: The invention relates to a human immunoglobulin G composition characterized in that the human immunoglobulin G concentration is at least 230 g/l, which is of use in particular for subcutaneous administration.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: November 17, 2015
    Assignee: Laboratoire Francais Du Fractionnement Et Des Biotechnologies
    Inventors: Sylvain Huille, Laetitia Cohen-Tannoudji, Florence Arvis, Alexandra Paillard
  • Method for preparing a concentrate of factor XI
    Patent number: 9181323
    Abstract: The invention concerns a concentrate of human Factor XI having high specific activity prepared using a method comprising a filtration-adsorption step and a chromatography step on cation exchange resin. The concentrate obtained is fully adapted for therapeutic use as substitution therapy in cases of Factor XI deficiency.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: November 10, 2015
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventor: Jean-François Martin
  • Method for purifying or detecting a target protein
    Patent number: 9175034
    Abstract: A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: November 3, 2015
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Laurent Siret, Abdessatar Chtourou, Frédéric Dhainaut, Gérald Perret
  • Optimized FC variants
    Patent number: RE45992
    Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: May 3, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars